Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer

• Published in: Medicinskij sovet no. 20; pp. 156 - 159
• Main Authors: Frolova, M. A., Stenina, M. B.
• Format: Journal Article
• Language: English; Russian
• Published: Remedium Group LLC 12.12.2021
• Subjects: double anti-her2 blockade; eribulin; her2-positive metastatic breast cancer; pertuzumab; trastuzumab
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2021-20-156-159

In recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in  the  highest life expectancy for  these patients among all subtypes. The  addition of  pertuzumab to trastuzumab and docetaxel has been shown to increase overall survival and is therefore recognized as the standard first-line treatment. The most optimal second-line treatment option is trastuzumab emtansine. In  addition, various combinations of  cytostatics and anti HER2 targeting agents can be used. The choice of treatment options in heavily pretreated patients is of great interest. If they have not previously received pertuzumab, is it worth to use it and which combination is the best? One possible option is the combination of eribulin with the dual anti-HER2 blockade with trastuzumab and pertuzumab. Eribulin is an anti-microtubule agent that irreversibly blocks mitosis. In addition, it has non-mitotic effects – in vivo and in vitro experiments demonstrated its ability to restore normal tumor vascularization, reduce the area of hypoxia and, as a consequence, decrease tumor cells migration and invasion. This article represents a clinical case of the use of eribulin with double anti-HER2 blockade in the 6th line of treatment in a patient with metastatic HER2-positive breast cancer. Long-term control of the disease (within 2 years) with a satisfactory quality of life has been demonstrated.